AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab
By Lee Cranmer, MD/PhD/FACP
The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment.
Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab
By Lee Cranmer, MD/PhD/FACP
The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment.
Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab
By Lee Cranmer, MD/PhD/FACP
The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment.
ASCENT-03, ASCENT-04, and Dato-DXd: How ADCs Are Replacing Chemotherapy in Metastatic TNBC
By Vijayakrishna Gadi, PhD, MD
ADCs are now first-line options in metastatic TNBC regardless of PD-L1 status. Dr. VK Gadi breaks down ASCENT-03, ASCENT-04, and Dato-DXd—and what's coming next in a rapidly shifting treatment landscape.
ASCENT-03, ASCENT-04, and Dato-DXd: How ADCs Are Replacing Chemotherapy in Metastatic TNBC
By Vijayakrishna Gadi, PhD, MD
ADCs are now first-line options in metastatic TNBC regardless of PD-L1 status. Dr. VK Gadi breaks down ASCENT-03, ASCENT-04, and Dato-DXd—and what's coming next in a rapidly shifting treatment landscape.
ASCENT-03, ASCENT-04, and Dato-DXd: How ADCs Are Replacing Chemotherapy in Metastatic TNBC
By Vijayakrishna Gadi, PhD, MD
ADCs are now first-line options in metastatic TNBC regardless of PD-L1 status. Dr. VK Gadi breaks down ASCENT-03, ASCENT-04, and Dato-DXd—and what's coming next in a rapidly shifting treatment landscape.
"I Think of Myself as a Plumber": The Engineer Trying to Fix Global Diagnostic Inequity
By Ariana Sutherland, MSc
"I think of myself as a plumber by training," Ayokunle Olanrewaju, PhD, says to a room of oncology healthcare providers.
"I Think of Myself as a Plumber": The Engineer Trying to Fix Global Diagnostic Inequity
By Ariana Sutherland, MSc
"I think of myself as a plumber by training," Ayokunle Olanrewaju, PhD, says to a room of oncology healthcare providers.
"I Think of Myself as a Plumber": The Engineer Trying to Fix Global Diagnostic Inequity
By Ariana Sutherland, MSc
"I think of myself as a plumber by training," Ayokunle Olanrewaju, PhD, says to a room of oncology healthcare providers.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
Prostate Cancer in 2026: Personalizing ADT Duration, PARP Inhibitors Move Earlier, and a Bispecific That May Finally Crack Immunotherapy in This Disease
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
Prostate Cancer in 2026: Personalizing ADT Duration, PARP Inhibitors Move Earlier, and a Bispecific That May Finally Crack Immunotherapy in This Disease
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
Prostate Cancer in 2026: Personalizing ADT Duration, PARP Inhibitors Move Earlier, and a Bispecific That May Finally Crack Immunotherapy in This Disease
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
What Does Oncology Have to Do With Advocacy, Anyway?
By Ariana Sutherland, MSc
Ask a room full of oncologists who among them is an advocate, and most hands stay down. Now ask whether they educate patients about their care, push back on insurance denials, or speak up when something is wrong.
What Does Oncology Have to Do With Advocacy, Anyway?
By Ariana Sutherland, MSc
Ask a room full of oncologists who among them is an advocate, and most hands stay down. Now ask whether they educate patients about their care, push back on insurance denials, or speak up when something is wrong.
What Does Oncology Have to Do With Advocacy, Anyway?
By Ariana Sutherland, MSc
Ask a room full of oncologists who among them is an advocate, and most hands stay down. Now ask whether they educate patients about their care, push back on insurance denials, or speak up when something is wrong.